StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
No sell-side coverage available for PMI yet.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-18 | $0.16 | $0.17 | +4.23% | 340.1M |
| 05-19 | $0.15 | $0.16 | +4.24% | 15.1M |
| 05-20 | $0.16 | $0.15 | -5.52% | 7.5M |
| 05-21 | $0.15 | $0.14 | -5.37% | 5.1M |
| 05-22 | $0.14 | $0.15 | +5.74% | 11.6M |
Picard Medical Inc operates through its wholly owned subsidiary, a medical technology company focused on developing, manufacturing, and commercializing the SynCardia TAH, an implantable total artificial heart system. The company is engaged in designing, manufacturing, producing, supplying, marketing, and selling medical device products, including the SynCardia TAH, which is designed to assume the full function of a failed human heart in patients suffering from advanced heart failure. The SynCardia TAH replaces both the left and right ventricles as well as all four heart valves.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q1 2025 2025-03-31 |
|---|---|---|---|---|
Revenue | $1.15M | $4.94M | $3.93M | $620.00K |
Operating Income | $-4.51M | $-13.26M | $-10.25M | $-3.25M |
Net Income | $-7.62M | $-27.00M | $-22.71M | $-5.56M |
EPS (Diluted) | $-0.10 | $-0.75 | $-0.96 | $-0.80 |
Total Assets | $11.22M | $22.55M | $13.52M | Not available |
Total Liabilities | $12.67M | $18.76M | $5.55M | Not available |
Cash & Equivalents | $121.00K | $7.45M | $2.81M | Not available |
Free Cash Flow OCF − CapEx | $-3.83M | Not available | Not available | $-2.24M |
Shares Outstanding | 75.26M | 73.70M | 73.70M | 7.96M |
Latest Form 13F-HR disclosures from the curated Super Investors list. Click through to see each manager's full long book.